The footprints of cancer development: Cancer biomarkers

被引：101

作者：

Ullah, Mohd. Fahad ^{[1
]}

Aatif, Mohammad ^{[1
]}

机构：

[1] Aligarh Muslim Univ, Fac Life Sci, Dept Biochem, Aligarh 202002, Uttar Pradesh, India

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 03期

关键词：

Biomarkers; Diagnosis; Proteomics; Cancer; Microarray profile; PROSTATE-SPECIFIC ANTIGEN; MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENE; PLASMINOGEN-ACTIVATOR SYSTEM; HUMAN TISSUE KALLIKREINS; METHYLACYL-COA RACEMASE; MICRORNA EXPRESSION; PROMOTER HYPERMETHYLATION; DIFFERENTIAL EXPRESSION; CYSTEINE CATHEPSINS;

D O I：

10.1016/j.ctrv.2008.10.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diagnostic detection and measurement of cancer disease progression are essential elements for successful cancer disease management. The early stages of cancer development carry the maximum potential for therapeutic interventions. However, these stages are often asymptomatic, leading to delayed diagnosis at the very advanced stages when effective treatments are unavailing. The application of biomarkers to cancer is leading the way because of the unique association of genomic changes in cancer cells with the disease process. They have the potential to not only help identify who will develop cancer but also to predict as to when the event is most likely to occur. In recent years, there has been an enormous effort to develop specific and sensitive biomarkers for precise and accurate screening, diagnosis, prognosis and monitoring of high risk cancer to assist with therapeutic decisions. The present article is a brief review of the emerging trends in the development of biomarkers for early detection and precise evaluation of cancer disease. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：193 / 200

页数：8

共 148 条

[91] Cysteine cathepsins: multifunctional enzymes in cancer [J].

Mohamed, Mona Mostafa ;

Sloane, Bonnie F. .

NATURE REVIEWS CANCER, 2006, 6 (10) :764-775

[92]

Montenarh M., 2000, Cancer and Autoimmunity, P193

[93] Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues [J].

Murakami, Y ;

Yasuda, T ;

Saigo, K ;

Urashima, T ;

Toyoda, H ;

Okanoue, T ;

Shimotohno, K .

ONCOGENE, 2006, 25 (17) :2537-2545

[94] Autoantibody cancer biomarker: Extracellular protein kinase A [J].

Nesterova, Maria V. ;

Johnson, Natalie ;

Cheadle, Christopher ;

Bates, Susan E. ;

Mani, Sridhar ;

Stratakis, Constantine A. ;

Kahn, Islam ;

Gupta, Rishab K. ;

Cho-Chung, Yoon S. .

CANCER RESEARCH, 2006, 66 (18) :8971-8974

[95] Nanotechnology applications in cancer [J].

Nie, Shuming ;

Xing, Yun ;

Kim, Gloria J. ;

Simons, Jonathan W. .

ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, 2007, 9 :257-288

[96] Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays [J].

Nishizuka, S ;

Charboneau, L ;

Young, L ;

Major, S ;

Reinhold, WC ;

Waltham, M ;

Kouros-Mehr, H ;

Bussey, KJ ;

Lee, JK ;

Espina, V ;

Munson, PJ ;

Petricoin, E ;

Liotta, LA ;

Weinstein, JN .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14229-14234

[97] Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma [J].

O'Day, SJ ;

Gammon, G ;

Boasberg, PD ;

Martin, MA ;

Kristedja, TS ;

Guo, M ;

Stern, S ;

Edwards, S ;

Fournier, P ;

Weisberg, M ;

Cannon, M ;

Fawzy, NW ;

Johnson, TD ;

Essner, R ;

Foshag, LJ ;

Morton, DL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2752-2761

[98]

Obiezu CV, 2001, CLIN CANCER RES, V7, P2380

[99] Cysteine cathepsin proteases as pharmacological targets in cancer [J].

Palermo, Carmela ;

Joyce, Johanna A. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (01) :22-28

[100] Human tissue kallikreins: The cancer biomarker family [J].

Paliouras, Miltiadis ;

Borgono, Carla ;

Diamandis, Eleftherios P. .

CANCER LETTERS, 2007, 249 (01) :61-79

← 5 6 7 8 9 10 11 12 13 14 →